About this trial
This study aims to identify early-stage type 1 diabetes (T1D) in children aged 2-6 and 8-10 years through autoantibody (Ab) screening, genetic and immunological analyses, and to evaluate the effectiveness of educational interventions, as well as the feasibility and acceptability of their implementation.
It is a prospective cohort study involving 2,169 children attending primary healthcare centres in the Barcelonès area. Eligible participants will be those engaged in routine paediatric preventive programe with parental informed consent. The screening process consists of three visits: Visit 1: Capillary blood collection for 3 T1D related Ab (3-screen ELISA). Visit 2: Confirmation of positive results through a new venous blood sample to determine single T1D related Ab and metabolic tests (fasting glucose, HbA1c, C-peptide), HLA, imme cell study. Visit 3: Risk stratification based on Ab presence: Group A (negative), Group B (one positive Ab, at risk of T1D), and Group C (two positive Ab, diagnosed at stage 1 or 2). Immunological and metabolic changes will be monitored, and screening effectiveness will be assessed in terms of sensitivity, specificity, and false positive/negative rates. The association between HLA genotype and Ab positivity will be analysed using logistic regression. A cost-effectiveness analysis will be conducted alongside a qualitative evaluation of parents' and stakeholders' perceptions regarding the screening process.This study will provide evidence to optimise early T1D detection and its implementation in primary care.
Eligibility criteria
Qualifiers
Young children: 2-6 years
Older children: 7-10 years
Attendance at routine pediatric visits within the Preventive Activities and Health Promotion Programme in Childhood in Catalonia ("Creixer amb Salut") at the specified ages (2-10 years)
Written informed consent provided by parents or legal guardians
Disqualifiers
Presence of primary immunodeficiency
Current treatment with immunosuppressive therapy
Ongoing participation in another clinical trial
Refusal to participate or inability to comply with study procedures
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Locations
Sponsors and collaborators
Fabiana Sherine Ganem dos Santos
Lead sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Sponsor institution
Germans Trias i Pujol Research Institute | IGTP
Collaborator
Institut de Recerca Germans Trias i Pujol
Collaborator